J.P. Morgan analyst Lisa Gill maintained a Buy rating on McKesson (MCK – Research Report) on February 4 and set a price target of $316.00. The company’s shares closed last Friday at $271.19, close to its 52-week high of $282.73.
According to TipRanks.com, Gill is a 5-star analyst with an average return of 15.8% and a 61.1% success rate. Gill covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Alignment Healthcare, and Bright Health Group.
Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $301.31, representing a 10.3% upside. In a report issued on February 8, Cowen & Co. also maintained a Buy rating on the stock with a $325.00 price target.
McKesson’s market cap is currently $40.62B and has a P/E ratio of 30.50.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MCK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1833, Texas-based McKesson Corp. provides pharmaceuticals, health information technology, medical supplies, and care management tools. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions.
Read More on MCK:
- Fortinet (FTNT) Receives a Sell from J.P. Morgan
- J.P. Morgan Reaffirms Their Hold Rating on Regeneron (REGN)
- J.P. Morgan Thinks Replimune Group’s Stock is Going to Recover
- Century Communities (CCS) Gets a Buy Rating from J.P. Morgan
- Analysts Offer Insights on Materials Companies: Berry Global Group (BERY) and Amcor (AMCR)